Document Detail

Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
MedLine Citation:
PMID:  20934769     Owner:  NLM     Status:  MEDLINE    
We analyzed the medical records of 884 type 2 DM patients who were taking different antiplatelet agents for more than 2 years. Based on the records, occurrences of cardiovascular events for 10 years were evaluated. The composite disease-free survival rate for cilostazol monotherapy group was similar to aspirin subgroup (p=0.133).
Sang Youl Rhee; Young Seol Kim; Suk Chon; Seungjoon Oh; Jeong-Taek Woo; Sung Woon Kim; Jin-Woo Kim
Related Documents :
7747499 - Treatment of nonvalvular atrial fibrillation.
6642779 - Clinical features and long-term natural history of the postpericardiotomy syndrome.
17263709 - Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagul...
15976329 - Recurrence rate after a first venous thrombosis in patients with familial thrombophilia.
8339409 - Comparison of native prothrombin antigen with the prothrombin time for monitoring oral ...
646249 - Ovarian (corpus luteum) hemorrhage during anticoagulation therapy.
23267169 - Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic...
8724089 - Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral d...
17664049 - Dexamethasone decreases cerebrospinal fluid soluble tumor necrosis factor receptor 1 le...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-08
Journal Detail:
Title:  Diabetes research and clinical practice     Volume:  91     ISSN:  1872-8227     ISO Abbreviation:  Diabetes Res. Clin. Pract.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-28     Completed Date:  2011-05-05     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  8508335     Medline TA:  Diabetes Res Clin Pract     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  e11-4     Citation Subset:  IM    
Copyright Information:
2010 Elsevier Ireland Ltd. All rights reserved.
Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / therapeutic use
Cardiovascular Diseases / epidemiology,  prevention & control
Cerebrovascular Disorders / epidemiology,  prevention & control
Diabetes Mellitus, Type 2 / complications*,  drug therapy*
Diabetic Angiopathies / epidemiology,  prevention & control*
Disease-Free Survival
Drug Therapy, Combination
Medical Records
Middle Aged
Peripheral Arterial Disease / epidemiology,  prevention & control
Platelet Aggregation Inhibitors / therapeutic use*
Proportional Hazards Models
Republic of Korea / epidemiology
Retrospective Studies
Tetrazoles / therapeutic use*
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Tetrazoles; 50-78-2/Aspirin; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric c...
Next Document:  Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to i...